Biodistribution of Bevacizumab in Peritoneal Metastatic Models of Gastric Cancer: A New Study Offers Insights

Strategic Insights -

Researchers in Kanazawa, Japan, have conducted a study to investigate the biodistribution of bevacizumab in peritoneal metastatic models of gastric cancer. The aim of the study was to clarify which method of therapy, systemic or regional, is more effective in treating peritoneal metastasis. A highly peritoneal-seeding cell line of gastric cancer, OCUM-2MD3, was used in the study, which exhibited high production and release of VEGF. The biodistribution of bevacizumab was investigated using peritoneal metastatic models together with subcutaneous xenografts.

Key Takeaways:

  • The study found that intraperitoneal administration of (125)I-bevacizumab resulted in low peritoneal clearance, while subcutaneous administration showed preferential accumulation in subcutaneous tumors and peritoneal nodules, with a high blood concentration.
  • The effects of bevacizumab were found to inhibit the growth of peritoneal nodules in both subcutaneous and intraperitoneal administration models.
  • The study concluded that bevacizumab should be administered systemically rather than regionally for the treatment of peritoneal metastasis of gastric cancer.
  • The combination of bevacizumab with intraperitoneal paclitaxel showed potential for treating patients with peritoneal metastasis of gastric cancer.
  • Yagi and colleagues published their study in Cancer Chemotherapy and Pharmacology, highlighting the importance of systemic administration of bevacizumab in treating peritoneal metastasis.
  • The study provides valuable insights into the treatment of gastric cancer and the effectiveness of bevacizumab in combination with paclitaxel.

Statistics:

  • 445 words, including references (Cancer Chemotherapy and Pharmacology, 2010;66(4):745-53).
  • The study involved the use of peritoneal metastatic models with subcutaneous xenografts of gastric cancer in mice.
  • (125)I-radiolabelled bevacizumab was administered to the models subcutaneously or intraperitoneally, and the biodistribution was investigated.
  • The anti-tumor response of bevacizumab and paclitaxel was assessed as single agents or in combination using peritoneal metastatic models.

Sources:

  • Yagi et al. (2010) Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemotherapy and Pharmacology, 66(4), 745-53.